In a wrapup of technology and life science news being reported by Triangle media outlets:
- TransEnterix cuts jobs after FDA rejects robot
- G1 Therapeutics adds to a big fundraiser
- A look at the joint UNC-NCSU biomedical engineering effort
- TransEnterix cuts jobs
TransEnterix cut one third of its work force following the recent FDA rejection of a robotic surgery system as it shifts emphasis to another system it hopes to win approval for next year, reports The News and Observer.
“The layoffs took place in Morrisville, where the company now employs 75 people, down from 136 last month. TransEnterix’s staff in Europe has grown from 20 to 30 as the company redoubles its efforts to sell its ALF-X robot in Europe and later in the Middle East and Asia,” the Raleigh newspaper says.
Read the details at:
- G1 Therapeutics raises $47 million
After raising $33 million last year and $12.5 million in 2014, Chapel Hill-based G1 Therapeutics has wrapped up a $47 million fundraiser.
“Investors include local venture capital groups like Hatteras Venture Partners and Eshelman Ventures. However, in the latest round, G1 disclosed that total investors have doubled from 10 to 20 groups and included new investors Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital,” notes The Triangle Business Journal.
Read more at:
- Profiling joint NCSU-UNC research effort
Xconomoy offers a detailed look inside a joint research effort at NCSU and UNC-Chapel Hill.
“[A] smart insulin patch is one of a number of technologies in development at the joint biomedical engineering department at NC State and UNC. Beyond teaching biomedical engineering, the program also pursues research with potential applications in drug delivery, regenerative medicine, and medical imaging. Nancy Allbritton, chair of the department, says the research is an effort to keep pace with industry trends bridging medicine and engineering,” reports Frank Vinluan.
See the full story at: